| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 26/06/2023 | 12:03 | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NYSE:LCI | Lannett Company Inc |
| 20/06/2023 | 12:53 | Edgar (US Regulatory) | Termination of Registration of a Class of Security Under Section 12(g) (15-12g) | NYSE:LCI | Lannett Company Inc |
| 20/06/2023 | 12:52 | Edgar (US Regulatory) | Post-effective Amendment to an S-8 Filing (s-8 Pos) | NYSE:LCI | Lannett Company Inc |
| 20/06/2023 | 12:48 | Edgar (US Regulatory) | Current Report Filing (8-k) | NYSE:LCI | Lannett Company Inc |
| 15/05/2023 | 22:32 | Edgar (US Regulatory) | Quarterly Report (10-q) | NYSE:LCI | Lannett Company Inc |
| 04/05/2023 | 16:20 | Edgar (US Regulatory) | Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse) | NYSE:LCI | Lannett Company Inc |
| 01/05/2023 | 12:55 | PR Newswire (US) | Lannett Company, Inc. Enters Into Restructuring Support Agreement | NYSE:LCI | Lannett Company Inc |
| 20/04/2023 | 12:53 | PR Newswire (US) | NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS | NYSE:LCI | Lannett Company Inc |
| 04/04/2023 | 12:55 | PR Newswire (US) | LANNETT SHARES UPDATE | NYSE:LCI | Lannett Company Inc |
| 10/02/2023 | 15:47 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NYSE:LCI | Lannett Company Inc |
| 01/02/2023 | 22:15 | PR Newswire (US) | LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE | NYSE:LCI | Lannett Company Inc |
| 25/01/2023 | 22:30 | PR Newswire (US) | LANNETT ANNOUNCES 1 FOR 4 REVERSE STOCK SPLIT | NYSE:LCI | Lannett Company Inc |
| 25/01/2023 | 12:52 | PR Newswire (US) | LANNETT TO REPORT FISCAL 2023 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, FEBRUARY 1 | NYSE:LCI | Lannett Company Inc |
| 04/01/2023 | 12:52 | PR Newswire (US) | LANNETT PROVIDES DEVELOPMENT UPDATE ON BIOSIMILAR INSULIN PRODUCTS | NYSE:LCI | Lannett Company Inc |
| 18/11/2022 | 22:10 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NYSE:LCI | Lannett Company Inc |
| 10/11/2022 | 22:14 | Edgar (US Regulatory) | Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) | NYSE:LCI | Lannett Company Inc |
| 07/11/2022 | 12:52 | PR Newswire (US) | LANNETT ANNOUNCES PATENT LICENSES FOR THE PEN INJECTOR DELIVERY DEVICE TO BE USED FOR ITS INSULIN GLARGINE AND INSULIN ASPART DEVELOPMENT PROGRAM | NYSE:LCI | Lannett Company Inc |
| 02/11/2022 | 21:15 | PR Newswire (US) | LANNETT REPORTS BETTER THAN EXPECTED FINANCIAL RESULTS FOR FISCAL 2023 FIRST-QUARTER; REITERATES FULL-YEAR GUIDANCE | NYSE:LCI | Lannett Company Inc |
| 26/10/2022 | 12:52 | PR Newswire (US) | LANNETT TO REPORT FISCAL 2023 FIRST-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, NOVEMBER 2 | NYSE:LCI | Lannett Company Inc |
| 21/10/2022 | 12:53 | PR Newswire (US) | LANNETT RECEIVES FDA APPROVAL TO MANUFACTURE NUMBRINO® AT SEYMOUR PLANT | NYSE:LCI | Lannett Company Inc |
| 19/10/2022 | 12:55 | PR Newswire (US) | LANNETT ANNOUNCES SALE OF SEVERAL DISCONTINUED GENERIC DRUGS | NYSE:LCI | Lannett Company Inc |
| 31/08/2022 | 12:53 | PR Newswire (US) | LANNETT ANNOUNCES SUBJECT DOSING COMPLETE FOR PIVOTAL CLINICAL TRIAL OF BIOSIMILAR INSULIN GLARGINE | NYSE:LCI | Lannett Company Inc |
| 25/08/2022 | 14:11 | Edgar (US Regulatory) | Annual Report (10-k) | NYSE:LCI | Lannett Company Inc |
| 24/08/2022 | 22:15 | PR Newswire (US) | LANNETT REPORTS FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS | NYSE:LCI | Lannett Company Inc |
| 19/08/2022 | 12:52 | PR Newswire (US) | LANNETT TO REPORT FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, AUGUST 24 | NYSE:LCI | Lannett Company Inc |
| 01/06/2022 | 12:52 | PR Newswire (US) | LANNETT PROVIDES UPDATE ON PIVOTAL CLINICAL TRIAL FOR BIOSIMILAR INSULIN GLARGINE | NYSE:LCI | Lannett Company Inc |
| 12/05/2022 | 12:52 | PR Newswire (US) | LANNETT ENTERS AGREEMENT TO BE EXCLUSIVE U.S. DISTRIBUTOR OF FLUDARABINE PHOSPATE FOR INJECTION, USP | NYSE:LCI | Lannett Company Inc |
| 04/05/2022 | 22:15 | PR Newswire (US) | LANNETT REPORTS FISCAL 2022 THIRD-QUARTER FINANCIAL RESULTS | NYSE:LCI | Lannett Company Inc |
| 27/04/2022 | 12:52 | PR Newswire (US) | LANNETT TO REPORT FISCAL 2022 THIRD-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, MAY 4 | NYSE:LCI | Lannett Company Inc |
| 29/03/2022 | 12:52 | PR Newswire (US) | LANNETT INITIATES PIVOTAL CLINICAL TRIAL FOR BIOSIMILAR INSULIN GLARGINE | NYSE:LCI | Lannett Company Inc |